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Introduction

The vexing question of optimal glucose level in the intensive care unit has long perplexed intensivists.
Hyperglycemia is a natural response to physiologic stress,1 and in the critically ill patient has been
attributed to inflammatory processes, insulin counter-regulatory hormones, organ dysfunction,
iatrogenic carbohydrate or medication related hyperglycemia, and insulin resistance as evidenced
by concurrently elevated insulin levels.1 Hyperglycemia occurs in 50-75% of patients admitted to
an ICU, and has been associated with various adverse outcomes including increased mortality,
organ dysfunction, susceptibility to infections, and neurological complications.1,2 On the cellular
level, tissue/organ damage is theorized to be mediated via the production of toxic polyol metabolites
and reactive oxygen species,3 with compromise of mitochondrial/cellular function.1 At the opposite
extreme, hypoglycemia is acutely detrimental and clearly mandates avoidance. Glucose variability
has also been linked to adverse outcomes,4 and insulin administration itself has been associated
with increased mortality.5 As such, it is believed that resolution of hypoglycemia, and not insulin
administration, is the determinant of improved outcomes.5
The dilemma facing intensive care physicians therefore lies in achieving a balance between the
two detrimental extremes of hyperglycemia and hypoglycemia. Despite the completion of large
randomized multicenter trials, the ideal glucose range to which treatment is targeted remains
uncertain, and in fact there remains speculation as to whether glucose levels require treatment at
all. Nevertheless, a familiarity with the available literature is imperative for the intensivist aspiring
to achieve desirable outcomes for patients. The preponderance of literature pertaining to glycemic
management in the ICU comes from non-neurological patients, and data regarding optimal glucose
control in the NICU is therefore scant. As such, this article will review the available literature
pertaining to hyperglycemic management in the ICU, with particular attention to patients with
neurological conditions.

Complications of Hyperglycemia

Multiple studies have demonstrated an association between hyperglycemia and adverse outcomes,
including mortality, and morbidity in terms of systemic multi-organ dysfunction and various
adverse neurological outcomes. Systemic morbidity from hyperglycemia has included such adverse
events as respiratory failure in the form of prolonged ventilator dependence, renal insufficiency,
anemia and greater need for transfusions, and increased risk for infections and sepsis.6,7 Neurological
consequences have involved elevations in intracranial pressure, cerebral herniation, greater frequency
of epileptic episodes, ICU related polyneuromyopathy, and unfavorable outcomes based on measures
of functional status.8,9 Hyperglycemia has been identified as a predictor of unfavorable outcomes
in trauma patients,10 and in those with cardiovascular and cerebrovascular disease,11,12 and in SAH
hyperglycemia has been related to the occurrence of vasospasm and poor outcome.8 Observational
studies comparing intensive insulin therapy (IIT) to conventional therapy have suggested a possible
benefit to IIT in terms of mortality and organ failure,5,13 obviating the need for more conclusive
clinical trials.

Randomized Clinical Trials

Several large randomized trials have attempted to identify an optimal glucose range within which
favorable outcomes are maximized and adverse events minimized. In a prospective, randomized,
controlled (but unblinded) landmark study of 1548 SICU patients, IIT (target glucose levels 80-100mg/
dl) was compared to conventional therapy (glucose 180-200mg/dl).7 Intensive therapy resulted in a
lower morality rate (4.6% vs. 8%), mostly in those with ICU stays >5 days, and mostly in those
dying from sepsis and multi-organ failure.7 IIT also reduced overall in-hospital mortality, duration
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of ventilator dependence, acute renal failure,
hyperbilirubinemia, anemia, bacteremia, and
critical illness polyneuropathy.7
In a follow-up study with similar methodology
(but blinded) of 1200 MICU patients, IIT to
keep glucose levels between 80-110mg/dl was
compared to conventional therapy aiming
at levels below 180mg/dl.14 In this study, IIT
had no impact upon mortality, yet reduced
duration of ventilatory support, acute renal
failure, and ICU stay.14 Interestingly, among
patients treated with IIT, those who stayed in
the ICU for 3 or more days had less in-hospital
mortality whereas those staying for less time
had increased in-hospital mortality, and those
staying for 7 or more days had lower rates of
neurological complications.14 IIT patients also
experienced more episodes of hypoglycemia,
which may have been in part due to the greater
frequency of patients with renal and hepatic
failure in the MICU.14
In a randomized unblinded single-center study
of 504 MICU and SICU patients, treatment
strategies comparing goal glucose levels
between 80-110mg/dl and 180-200mg/dl were
compared.15 Mortality rates were similar between
the two (36.6% vs. 32.4%), but hypoglycemic
episodes were greater in the IIT group (8.5% vs.
1.7%).15 In the VISEP* study of over 600 septic
patients, which was terminated prematurely
for safety reasons, IIT [glucose 80-110mg/
dl] was associated with a greater rate of severe
hypoglycemia (17% vs. 4.1%) and more frequent
serious adverse events (10.9% vs. 5.2%), red-cell
transfusions, and duration of ICU stay, than
conventional therapy [180-200mg/dl].16
The GLUCONTROL study of 1078 medical
and surgical ICU patients was also terminated
prematurely due to safety reasons and excessive
protocol violations, but demonstrated that IIT
[glucose 80-110mg/dl] versus intermediate
glucose control [140-180mg/dl] resulted in
similar mortality rates (15.3% vs. 17.2%).17
Hypoglycemic events were also increased by
IIT (8.7% vs. 2.7%), and a greater mortality
was observed in these patients.17 The NICESUGAR† study of 6104 general ICU patients
* Volume Substitution and Insulin Therapy in Severe Sepsis
†
 Normoglycemia in Intensive Care Evaluation – Survival Using

Cerebrovascular

revealed an increased mortality rate among
IIT patients [glucose 80-110mg/dl, 27.5%
mortality] compared to conventional therapy
[140-180mg/dl, 24.9% mortality] and greater
rates of hypoglycemia (6.8% vs.0.5%).18

Neurological Patients

In a subgroup analysis of patients with cerebral
injury from the original SICU study, most of
whom experienced a cerebrovascular event
or had neurosurgery for various reasons,
IIT resulted in a reduction in intracranial
pressures, epileptic episodes, critical illness
polyneuropathy, need for vasopressors,
and diabetes insipidus.9 In a small study of
head trauma patients, IIT resulted in more
hypoglycemic events, but no improvement in
mortality, neurological outcome, or infections.19
One retrospective study of patients with
subarachnoid hemorrhage showed no benefit
to aggressive hyperglycemic management in
terms of neurological outcome, vasospasm and
delayed cerebral ischemia.20
A prospective observational microdialysis study
of SAH patients found elevated glucose levels
to be associated with increased lactate/pyruvate
ratios and increased mortality.21 Conversely,
a more recent study of head trauma patients
showed that IIT resulted in lower cerebral
glucose concentrations (without a change in
cerebral glucose metabolic rate), with increases
in global oxygen extraction fraction.22 This
study also showed elevated lactate/pyruvate
ratios, and increased glutamate concentrations
in patients treated with IIT, particularly with
serum glucose levels below 80mg/dl.22 Mortality
did not differ between the intensive and regular
insulin therapy groups.22

Review Articles and Meta-Analyses

A review article focusing on the VISEP,
GLUCONTROL, and NICE-SUGAR studies
concluded that the available evidence supports
treatment of glucose levels >180mg/dl, thus
effectively discouraging aggressive glycemic
control as defined by most clinical trials, and
notes the potential for maximum benefit at
levels <140mg/dl.3 In assessing the available
data cumulatively, a 2008 meta-analysis of
over 8000 patients concluded that IIT reduces
risk for septicemia, but at the expense of more
hypoglycemic episodes (<40mg/dl) and without
any impact on in-hospital mortality.6 Current
guidelines for critically ill patients presented by
the American Diabetes Association recommend
starting treatment at glucose levels >180mg/dl,
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with a goal of maintaining levels <140mg/dl,
and discourage aggressive treatment to reach
levels <110mg/dl.23
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Despite the clear association between
hyperglycemia and adverse outcomes, clinical
studies have failed to definitively provide
evidence for a benefit to antihyperglycemic
therapy, and certainly have not identified a
precise target range for glucose levels. This leads
one to wonder whether hyperglycemia may
represent a physiological protective response,
and therefore a natural evolutionarily derived
reaction to illness that does not mandate
treatment. As recently stated by one author,
“the ultimate proof that hyperglycemia is an
independent risk factor for ICU mortality in
critically ill patients is lacking”.3
As is the case with many situations in medicine,
there is an innate belief that “abnormal”
laboratory values warrant correction. Until
the completion of trials demonstrating the
absence of benefit (and in fact a detriment)
from transfusions for anemia in ICU patients,
the belief was to normalize hemoglobin
counts so as to maintain levels of 10 or greater.
Now, with the completion of adequate trials,
the standard of care has become to allow
hemoglobin levels as low as 7.24 Thus, this
tendency to treat “abnormal” glucose values
may actually counteract a natural reactive (and
possibly protective) process, which may simply
represent the natural inclination by physicians
to assume a need for treatment of aberrant
values.
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